Home | Business News | Browse by Publication | M | M2 Presswire

PickThatMove.com June 22, 2009, We have picks REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN); KB Home (NYSE:KBH); Alcatel-Lucent (Euronext Paris and NYSE: ALU); Office Depot (NYSE:ODP) and Coeur d'Alene Mines Corporation (NYSE:CDE).

Article Excerpt
M2 PRESSWIRE-22 June 2009-PicksThatMove: PickThatMove.com June 22, 2009, We have picks REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN); KB Home (NYSE:KBH); Alcatel-Lucent (Euronext Paris and NYSE: ALU); Office Depot (NYSE:ODP) and Coeur d'Alene Mines Corporation (NYSE:CDE)(C)1994-2009 M2 COMMUNICATIONS

RDATE:22062009

-- REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) traded at $0.70 on the volume of 110,00 shares

RegeneRx Working with U.S. Military to Test TB4 Against Exposure to Chemical Agents in the Eye

BETHESDA, Md., Jun 22, 2009 -- REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) (the "Company" or "RegeneRx") announced today that it is collaborating with the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) and Dr. Gabriel Sosne, Associate Professor of Ophthalmology at Wayne State University, to evaluate TB4's (RGN-259 eye drops) ability to prevent or reduce damage to the eye caused by exposure to chemical agents. The ability to prevent or reduce such damage is the focus of substantial efforts by both the military and homeland security. The project will consist of a series of research experiments over the next twelve months with TB4, which is being commercially developed by RegeneRx and is in Phase II clinical trials.

RegeneRx Technology Background

TB4 is a synthetic version of a naturally occurring peptide present in virtually all human cells. It is a first-in-class multi-faceted molecule that promotes endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition, and down-regulates inflammation. RegeneRx has identified several molecular variations of TB4 that may affect the aging of skin, among other properties, and could...